Premium
HER2 assessment by bright‐field dual in situ hybridization in cell blocks of recurrent and metastatic breast carcinoma
Author(s) -
Edelweiss Marcia,
Sebastiao Ana Paula Martins,
Oen Handy,
Kracun Mihaela,
Serrette Rene,
Ross Dara S.
Publication year - 2019
Publication title -
cancer cytopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.29
H-Index - 57
eISSN - 1934-6638
pISSN - 1934-662X
DOI - 10.1002/cncy.22184
Subject(s) - medicine , breast cancer , breast carcinoma , concordance , metastatic breast cancer , immunohistochemistry , cancer , radiology , pathology , oncology
Background Breast cancer recurrences or metastases often are diagnosed using cytology material. Cell blocks (CBs) with adequate cellularity are crucial for the determination of accurate hormonal and human epidermal growth factor receptor 2 (HER2) status and to guide treatment. In the current study, the authors evaluated the concordance of HER2 status between bright‐field dual in situ hybridization (DISH), fluorescence in situ hybridization (FISH), and HER2 immunohistochemistry (IHC) performed on formalin‐fixed CBs of recurrent and metastatic breast cancers. Methods The authors searched for patients who had breast carcinoma recurrences or metastases diagnosed between 2010 and 2018 by fine‐needle aspiration or by the drainage of body cavity fluids with HER2 IHC and/or FISH performed on formalin‐fixed CBs. Cases with adequate tumor cellularity (>50 cells) were selected. HER2 DISH was performed on all CBs. HER2 status of the primary breast carcinoma was recorded. Results Formalin‐fixed CBs were identified from 30 patients with breast cancer recurrences and metastases in axillary lymph nodes (LNs) (5 patients), mediastinal LNs (8 patients), internal mammary LNs (1 patient), supraclavicular LNs (2 patients), portocaval LNs (1 patient), chest wall (3 patients), pleural fluid (3 patients), bone (4 patients), liver (2 patients), and lung (1 patient). All cases had HER2 IHC performed at the study institution and were scored by breast pathologists according to the American Society of Clinical Oncology/College of American Pathologists guidelines. The HER2 DISH results demonstrated 100% concordance (30 of 30 cases) with the concurrent IHC and/or FISH. Conclusions All methods of HER2 evaluation were found to accurately identify the amplification status. DISH can be used in tandem with IHC as a reflex assay instead of FISH and is an efficient and reliable method with which to determine HER2 amplification in formalin‐fixed CBs.